Boehringer Ingelheim extends Morphosys deal
This article was originally published in Scrip
Boehringer Ingelheimhas exercised its option to useMorphosys's "rapid maturation" (RapMAT) technology for faster antibody optimisation as part of the existing agreement between the two companies. The two companies began the collaboration in 2003 and Morphosys has installed its HuCAL GOLD antibody library at Boehringer Ingelheim's research site in Vienna, Austria, in 2005. RapMAT improves the options for identifying antibodies from the HuCAL libraries and reduces the time for generation of promising therapeutic lead molecules. Morphosys will receive annual user fees for RapMAT and HuCAL, and Boeringer Ingelheim continues to have the option to receive multiple exclusive licences on new therapeutic antibody programmes. The collaboration currently covers four active therapeutic antibody programmes in various indications.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.